Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD) study will be conducted to evaluate the safety, tolerability, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!